Dear Colleagues,

Members from the EHA and other organisations have done their best to come up with up-to-date recommendations on the management of COVID-19 in cancer patients. However, the most urgent question is almost impossible to answer: which therapies should be administered/continued and which therapies should be deferred/stopped?

To address this question, we are conducting a survey in collaboration with ESMO amongst experts in the respective fields to get a better understanding of the risks of respective (targeted) therapies and a summary of expert opinion. We hope this will be helpful for clinicians caring for cancer patients. We have learned from our previous survey and have made some aspects more specifics as well as modified the list of drugs.

We kindly invite you to participate in this survey which you will find here: Link [https://www.clinicalsurveys.net/uc/covid19_en_2/](https://www.clinicalsurveys.net/uc/covid19_en_2/)

This link can be used only once. We are planning to repeat this survey again in due course. Please be aware that this is a personal invitation and you are kindly invited to answer only the items concerning your field of expertise. We suggest answering the questions only if you have at least 10 patients with the drug in question in your current practice.

We kindly ask you to answer as soon as possible, the survey will be closed on 27 April 2020. Results will be made available shortly afterwards and we will notify as soon as they can be accessed.

Thank you very much,

on behalf of the

EHA Scientific Working Group
EHA SWG infectious diseases